Gene Therapy to Target GD2 for Oncology by Bristol-Myers Squibb for Osteosarcoma: Likelihood of Approval
Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Osteosarcoma.
Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Osteosarcoma.
What's Your Reaction?
